W-18 (drug)
W-18 (drug)
W-18 is a synthetic opioid analgesic that was first synthesized in the 1980s by a team of researchers at the University of Alberta. It is part of a series of compounds known as the W-series, which were initially developed for their potential analgesic properties.
Chemical Properties
W-18 is chemically classified as a benzodiazepine derivative, although it does not exhibit the typical effects associated with benzodiazepines. The chemical structure of W-18 is characterized by a complex arrangement of atoms that contribute to its potent analgesic effects.
Pharmacology
W-18 acts on the opioid receptors in the brain, which are responsible for mediating the effects of natural and synthetic opioids. Despite its classification as an opioid, W-18 does not bind to the mu-opioid receptor in the same way as traditional opioids like morphine or fentanyl. This unique binding profile contributes to its high potency and potential for abuse.
Effects and Potency
W-18 is reported to be extremely potent, with estimates suggesting it is up to 10,000 times more potent than morphine. This high potency raises significant concerns regarding its potential for overdose and toxicity. Users may experience effects similar to other opioids, including analgesia, euphoria, and respiratory depression.
Legal Status
Due to its high potency and potential for abuse, W-18 has been classified as a controlled substance in many countries. In the United States, it is listed as a Schedule I substance under the Controlled Substances Act, indicating that it has a high potential for abuse and no accepted medical use.
Synthesis and Discovery
W-18 was first synthesized by a team led by Dr. Edward Knaus at the University of Alberta. The compound was part of a larger research effort to develop new analgesics with improved safety profiles. However, W-18 and its analogs were not pursued for clinical development due to their extreme potency and potential for harm.
Related pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD